Reference number : 032-2020-2021-Q4-00010, amendment number : , agreement type : C, recipient legal name : ONCOVIR CANADA INC, recipient country : CA, recipient province : BC, recipient city : Vancouver, recipient postal code : nan, program name english : Innovation for Defence Excellence and Security Program, program name french : Programme d’innovation pour la défense, l’excellence et la sécurité, program purpose english : nan, program purpose french : nan, agreement title english : Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults, agreement title french : nan, agreement number : nan, agreement value : 2099792.0, agreement start date : 2021-03-18, agreement end date : 2022-03-31, description english : The overall goal of this project is to advance the clinical development of Poly-ICLC (Hiltonol®), a broad-spectrum antiviral drug candidate, as an innovative solution to strengthen medical preparedness against viral threats., description french : L'objectif  du projet est de faire progresser le développement clinique du Poly-ICLC (Hiltonol®), un candidat médicament antiviral à large spectre, comme solution innovante pour renforcer la préparation médicale contre les menaces virales., expected results english : nan, expected results french : nan, additional information english : nan, additional information french : nan, owner organization : dnd-mdn, owner organization title : National Defence | Défense nationale